Traws Pharma (NASDAQ: TRAW) filed a prospectus supplement to increase its at-the-market offering capacity by $3,128,399, according to a Securities and Exchange Commission filing.

The biopharmaceutical company previously sold 3,607,270 shares under its existing ATM agreement with Citizens JMP Securities for gross proceeds of approximately $7.7 million. The new filing expands the total amount available for future share sales under the agreement.

The company entered into the original ATM agreement with Citizens JMP Securities on March 10, 2025, which allows for the sale of common stock from time to time at market prices. The updated prospectus supplement amends the company's base prospectus dated July 11, 2023, and prior supplements from March and April 2025.

Under the expanded agreement, Traws Pharma may offer and sell additional shares with a maximum aggregate gross sales price of up to $3.1 million through Citizens JMP Securities. This amount is in addition to the proceeds already received from previous sales under the original agreement.

The prospectus supplement filing was dated May 22, 2026, and relates to the company's registration statement on Form S-3 filed with the SEC.